sures include environmental factors and antimicrobial drugs, as well as the human immune response. At the same time, such adaptations provide us with opportunities to respond with new vaccine antigens, such as annually updated influenza vaccines, 17 or new or different antiinfective agents. This back-and-forth struggle between human ingenuity and microbial adaptation reflects a perpetual challenge. 12, 18, 19 Infectious diseases are closely dependent on the nature and complexity of human behavior, since they directly reflect who we are, what we do, and how we live and interact with other people, animals, and the environment. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Infectious diseases are acquired specifically and directly as a result of our behaviors and lifestyles, from social gatherings, to travel and transportation, to sexual activity, to occupational exposures, to sports and recreational activities, to what we eat and drink, to our pets, to the environment -even to the way we care for the ill in hospitals and other health care environments. Moreover, microbial colonizing infections that lead to long-term carriage without disease (e.g., within the endogenous human microbiome) may influence the development of infections with exogenous microbes 31, 32 and also have an effect on general immunologic and physiologic homeostasis, 33, 34 including effects on nutritional status. Human microbiomes seem to reflect, and may even have helped to drive, human evolution. 35 In this struggle, infectious diseases are intimately and uniquely related to us through our immune systems. The human immune system, including the primitive innate system and the specific adaptive system, 36 has evolved over millions of years from both invertebrate and vertebrate organisms, developing sophisticated defense mechanisms to protect the host from microbes. 37 In effect, the human immune system evolved as a response to the challenge of invading pathogens. Thus, it is not by accident that the fields of microbiology and immunology arose and developed in close association long before they came to be considered distinct disciplines.
Dise a se Emergence a nd R eemergence
Because infectious pathogens are evolutionarily dynamic, the list of diseases they cause is everchanging and continually growing. Since newly emerging infectious agents do not arise spontaneously, they must recently have come from somewhere else, usually from animal infections, as occurred with HIV infection, influenza, and the severe acute respiratory syndrome. This interspecies transmission underscores the importance of interdigitating the study of human and animal diseases 19, 23, [38] [39] [40] and recognizing the central role that microbial reservoirs, including those in animals, vectors, and the environment, play in human infectious diseases. 19, 38 Preexisting or established infectious diseases also may reemerge in different forms, as in extensively drug-resistant tuberculosis, 41 or in different locations, as in West Nile virus infection in the United States, 42 to cause new epidemics (Table 2) . Indeed, many human infectious diseases seem to have patterns of evolution, sometimes played out over thousands of years, in which they first emerge and cause epidemics or pandemics, become unstably adapted to human populations, undergo periodic resurgences, and eventually become endemic with the potential for future outbreaks (Fig. 1) . 12, 19, 43, 44 His t or ic a l Per spec t i v e s a nd Cur r en t S tat us
Just over a decade before the publication of the first issue of the Journal, President George Washington died of an acute infectious disease believed to have been bacterial epiglottitis. 45 Wash- ington's life reflects the history of his era and provides both a window into infectious diseases two centuries ago and a benchmark for measuring our remarkable progress since then. Washington was born in 1732, just before the deadliest diphtheria epidemic on the North American continent. He was scarred by smallpox, survived multiple debilitating bouts of malaria, suffered wound infections and abscesses, nursed his brother on a tropical island as he died of tuberculosis, and even had an influenza pandemic named after him (the Washington influenza of 1789-1790). During his presidency, he stayed in the then-capital city of Philadelphia while most of the government fled during the nation's deadliest yellow fever epidemic. 5, 12 At the time of Washington's birth, there was no well-defined concept of infection or immunity, no vaccines, almost no specific or effective treatments for infectious diseases, 3, 46 and little idea that any treatment or public health measure could reliably control epidemic diseases. During Washington's lifetime, infectious diseases were the defining challenges of human existence. No one alive then could have imagined the astonishing breakthroughs that lay ahead. In this regard, it is noteworthy that almost all the major advances in understanding and controlling infectious diseases have occurred in the past two centuries (Table 3 and interactive timeline). Experimental animal-transmission studies that were conducted soon after the War of 1812 were followed by the development of better microscopes, which linked fungi to skin diseases and protozoa to mucosal diseases -for example, Alfred Donné's 1836 work with Trichomonas vaginalis and David Gruby's studies of Candida albicans in the early 1840s. The breakthroughs in the late 1800s, which taken together provided the compelling unifying principle of infectious diseases and must surely rank among the most important advances in the medical sciences, were the characterization of specific cultivatable microorganisms and proof of their association with specific diseases. This triumph was led by the work of Davaine and Koch in establishing anthrax as the first fully characterized infectious disease. 47, 48 This seminal process was facilitated by the development of defined criteria for establishing causality (Koch's postulates).
Additional breakthroughs followed quickly, including the discovery and characterization of pathogen-specific immune responses; the demonstration that when inactivated by heat or chemicals or grown under limiting conditions that changed certain biologic properties (e.g., attenuation), organisms or their products could safely stimulate protective responses in a host; and development of anti-infective serums and chemicals to destroy pathogens. Over the next 135 years, a wide array of vaccines and antibiotics and, more recently, antiviral agents have saved hundreds of millions of lives, greatly extended the human life span, and reduced untold suffering. Undeniably, these countermeasures against infectious disease rank among the greatest achievements in public health and medicine.
History reminds us that new challenges in infectious diseases will continue to emerge and re- emerge. We must be prompt in identifying them and devising new countermeasures. In this effort, we still follow the familiar pathway that was set down in the late 1800s for the identification and characterization, both clinical and epidemiologic, of the causative agent; the characterization of the human immune response to the pathogen; and the development of pathogen-specific diagnostic tests, treatment strategies, and public health prevention strategies such as vaccinations. 49 Di agnosis a nd Ch a r ac ter i z at ion of Patho gens
In the late 1800s, the realization that identifiable microbes caused specific diseases led to pathogenspecific medical diagnosis. Although the timehonored techniques of growing bacteria in broth or solid cultures and staining and examining them under microscopes are still important today, newer technologies have transformed the field of microbial diagnosis. Among the first emerging epidemic diseases to be identified by one such method was the hantavirus pulmonary syndrome, a centuriesold disease caused by an unknown phlebovirus (Sin Nombre) that was discovered unexpectedly in 1993 50 by the application of a then-novel molecular genetic technique, polymerase chain reaction (PCR). This followed quickly on the 1992 discovery of the previously unknown agent causing an infectious chronic condition, Whipple's disease. 51 Less than a year later, PCR-related subtraction techniques solved a century-old mystery of the cause of Kaposi's sarcoma, human herpesvirus 8. 52 Now, less than two decades later, sophisticated, highthroughput, rapid sequencing of the genomes of pathogens not only dramatically hastens initial identification but also detects individual genetic variants, 53 facilitating identification of the genetic basis of drug resistance. Additional gene-based diagnostic tools include microchips and other technologies that detect short sequences of many different genes or their proteins, allowing simultaneous diagnosis or diagnostic elimination of multiple pathogens. New serologic techniques such as enzyme-linked immunosorbent assay can be many times more sensitive than traditional techniques in detecting and measuring antibodies to pathogens. Furthermore, monoclonal antibody techniques, which involve the use of cellular clones to produce antibodies against specific pathogen epitopes, have been adapted for the purposes of diagnosis, identification of the molecular structures of pathogens, elucidation of the natural history and pathogenesis of infectious diseases, development of conformationally accurate immunogens to be used as vaccine candidates, 54 and even treatment. 55 Many of these data-rich approaches require sophisticated bioinformatics systems (e.g., phylogenetic comparisons and genome construction analyses).
Vac cine De v el opmen t
Vaccines against infectious diseases such as anthrax and rabies have been produced since the late 1870s. Only in the past half century, however, have technological advances in vaccination led to dramatic changes in the field of disease prevention. The World Health Organization now estimates that each year more than 120 different types of vaccines save 2.5 million lives and with optimal uptake could save an additional 2 million. 56 Trivalent combined inactivated and live attenuated poliomyelitis vaccines were licensed in 1955 and 1962, respectively; a live attenuated trivalent vac- Of an estimated 58.8 million annual deaths worldwide, approximately 15.0 million (25.5%) are believed to be caused by infectious diseases. Cause-specific mortality estimates are provided by the World Health Organization. 43, 44 The data do not include deaths from secondary infectious causes, such as rheumatic fever and rheumatic heart disease, liver cancer and cirrhosis, or other chronic diseases.
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Copyright © 2012 Massachusetts Medical Society. All rights reserved. cine against three unrelated diseases (measles, mumps, and rubella) was licensed in 1971; and a variety of vaccine approaches and platforms have been introduced since then. It is now possible to determine high-resolution crystallographic structures of pathogens and use this information to design vaccines directed at the most relevant epitopes in the microbe's complex structure, an approach known as structure-based vaccine design. 57 T r e atmen t
Successful treatment with pathogen-immune serum was another critical breakthrough of the late 19th century. 55 This approach to therapy also encouraged scientists to develop chemicals to kill the specific pathogens that they were regularly identifying. Ehrlich succeeded first in 1910 with his magic bullet against syphilis (arsphenamine, or salvarsan 58 ). Within two decades, a new generation of scientists was working on what would eventually be called antibiotics. As a result of these efforts, sulfa drugs were developed in 1936, and penicillin in 1943. 59, 60 In the United States, tuberculosis had been only partially controlled by public health measures and incompletely effective vaccines. 61 It was not until the introduction of specific antituberculosis therapy in the 1950s 62 that sanatoriums were emptied and cases of active disease were substantially reduced. Antibiotics have revolutionized the treatment of many other important bacterial infections and have saved many millions of lives since their introduction. When antiviral drugs were first developed in the 1960s, they did not seem to be particularly promising, with a few exceptions. In response to the HIV/AIDS pandemic, however, the development of antiretroviral drugs markedly expanded the arsenal of available antiviral agents and invigorated the research-and-development pathway for these important drugs. Effective combinations of powerful antiretroviral drugs have led to substantial prolongation of the lives of millions of persons with previously almost invariably fatal HIV infection, a true landmark in therapies for infectious diseases. 15, 63 All antibiotic and antiviral drugs, however, share an inherent weakness: the organisms against which they are directed almost invariably evolve mechanisms of resistance. Bacteria become resistant by a variety of mechanisms. 64 The evolution of antimicrobial resistance is enhanced by overuse of antibiotics in animals and by inappropriate use in humans. Many viruses, particularly RNA viruses such as influenza virus, rapidly develop mutations even in a single brief replication cycle. A number of approaches have been pursued to meet the ever-present challenge of antimicrobial resistance. The development of new classes of antibiotic, antiviral, and antiparasitic agents aimed at diverse microbial targets, often with the use of high-throughput screening of compounds, 65 is strengthening and broadening the therapeutic armamentarium. In addition, combination therapies (e.g., antiretroviral agents for HIV infection and multidrug approaches to tuberculosis) have proved to be successful in slowing the emergence of resistance.
Publ ic He a lth Achie v emen t s
Breakthroughs in the field of infectious diseases have had far-reaching effects, including the realization of the critical importance of clean water and basic sanitation and hygiene for the prevention of a great number of infectious diseases. In addition, disease-specific approaches to prevention and treatment have led in many cases to the widespread control of diseases that historically have caused substantial morbidity and mortality. 66 The treatment of infectious diseases is in itself a prevention measure, limiting or preventing transmission to others. Eradication, the ultimate goal in facing the threat of an established or emerging infectious disease, is no longer unrealistic. Specifically, in addition to the millions of lives saved by vaccines and antibiotics, certain infectious diseases have been eliminated from large regions of the world or even completely eradicated, an accomplishment rarely, if ever, seen in other medical disciplines. In 1980, smallpox became the first eradicated disease, 9 making this among the most momentous achievements in human disease control. In May 2011, the veterinary morbillivirus disease rinderpest was declared eradicated, and its presumed descendant, human measles virus, is now being targeted for eradication. 67 Poliomyelitis has been eliminated from several regions of the world, and it is hoped that within a reasonable period, it will be eradicated globally. 68 Dracunculiasis (guinea worm disease) is also almost completely eradicated. 69 health measures using the tools provided by basic and clinical research.
Ne w V is ta s
An unanticipated outcome of the explosion of information concerning the microbial world is the recognition that a growing number of chronic diseases that were once attributed to host, environmental, or lifestyle factors or to unknown causes are actually directly or indirectly caused by infectious agents that potentially can be controlled through prevention and treatment. For example, liver cancer and cirrhosis are complications of hepatitis B and C infections, cervical cancer is a complication of human papillomavirus (HPV) infection, and gastric and duodenal ulcers may result from Helicobacter pylori infection. [70] [71] [72] Vaccines against two of these agents, hepatitis B and HPV, are already in use, exemplifying the concept of cancer-preventing vaccines. H. pylori infection can be cured with antibiotics, and chronic hepatitis B and C infections are being treated by means of antiviral regimens with growing success rates. Certain autoimmune conditions have also been attributed to infections. For example, enteric microbes have been associated with inflammatory arthritides, and Campylobacter jejuni and certain viruses have been associated with the Guillain-Barré syndrome. 73 In addition, with new technologies and approaches, scientists are exploring new facets of microbiology, including the role of the human microbiome in maintaining homeostasis in the ecosystems of our bodies and its possible relationship to conditions such as obesity and inflammatory bowel disease. 74 The Per pe t ua l Ch a l l enge
We are living in a remarkable era. Almost all the major advances in understanding and controlling infectious diseases have occurred during the past two centuries, and momentous successes continue to accrue. These breakthroughs in the prevention, treatment, control, elimination, and potential eradication of infectious diseases are among the most important advances in the history of medicine. Nevertheless, because of the evolutionary capacity of infectious pathogens to adapt to new ecologic niches created by human endeavor, as well as to pressures directed at their elimination, we will always confront new or reemerging infectious threats. Our successes in meeting these threats have come not just from isolated scientific triumphs but also from broad approaches that complement the battle against infectious diseases on many different fronts, including constant surveillance of the microbial landscape, clinical and public health efforts, and efficient translation of new discoveries into disease-control applications. These efforts are driven by the necessity of expecting the unexpected and being prepared to respond when the unexpected occurs. It is a battle that has been well fought for more than two centuries but that will almost certainly still be raging, in now-unimagined forms, two centuries from now. The challenges are truly perpetual. Our response to these challenges must be perpetual as well.
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